KRAS Mutation Detection
Ordering Recommendation
Predicts response to anti-EGFR and MAPK pathway therapies in a variety of malignancies (eg, colorectal and lung cancer).
Submit With Order
Polymerase Chain Reaction/Pyrosequencing
DNA isolation: Sun-Sat
Mon, Wed, Fri
10-12 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Tumor tissue.  
Specimen Preparation
Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Transport tissue block or 5 unstained 5-micron slides. (Min: 3 slides) Transport block(s) and/or slide(s) in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect™ or contact ARUP Client Services at (800) 522-2787.  
Storage/Transport Temperature
Room temperature. Ship in cooled container during summer months.  
Unacceptable Conditions
Specimens fixed/processed in alternative fixatives (alcohol, Prefer). Frozen specimens. Decalcified specimens. Less than 25 percent tumor.  
Include surgical pathology report.  
Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable  
Reference Interval
Interpretive Data
Refer to report.

See Compliance Statement B:
This assay detects mutations in codons 12, 13, and 61.
CPT Code(s)
88381; 81275; 81403
Component Test Code*Component Chart Name
0040249KRAS Mutation Detection
2002148Block ID
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Cross References
  • anti-EGFR therapy resistance testing
  • Cetuximab (Erbitux)
  • Codon 12,13
  • Codon 61
  • KRAS codons 12, 13, 61
  • Panitumumab (Vectibix)
  • RAS